Quantum Biopharma Ltd. Files October 2024 6-K Report

Ticker: QNTM · Form: 6-K · Filed: Oct 22, 2024 · CIK: 1771885

Quantum Biopharma Ltd. 6-K Filing Summary
FieldDetail
CompanyQuantum Biopharma Ltd. (QNTM)
Form Type6-K
Filed DateOct 22, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, foreign-private-issuer

TL;DR

Quantum Biopharma (QNTB) filed its monthly 6-K, standard procedure for foreign issuers.

AI Summary

Quantum Biopharma Ltd. (formerly FSD Pharma Inc.) filed a Form 6-K on October 22, 2024. The report is for the month of October 2024 and indicates the company is a foreign private issuer filing under the 1934 Act. The company's principal executive office is located in Toronto, Ontario, Canada.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Quantum Biopharma Ltd.'s status as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine filing (6-K) that does not contain new financial results or significant operational updates.

Key Players & Entities

  • Quantum Biopharma Ltd. (company) — Registrant
  • FSD Pharma Inc. (company) — Former company name
  • Donal Carroll (person) — Chief Financial Officer
  • October 22, 2024 (date) — Filing date
  • Toronto, Ontario, Canada (location) — Principal executive office location

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers filed with the SEC to provide information that the issuer makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.

What was Quantum Biopharma Ltd.'s former name?

Quantum Biopharma Ltd.'s former name was FSD Pharma Inc., with a date of name change on March 27, 2019.

Who signed this Form 6-K filing on behalf of Quantum Biopharma Ltd.?

Donal Carroll, Chief Financial Officer, signed the Form 6-K filing on behalf of Quantum Biopharma Ltd.

Where is Quantum Biopharma Ltd.'s principal executive office located?

Quantum Biopharma Ltd.'s principal executive office is located at 55 University Ave., Suite 1003, Toronto, Ontario, M5J 2H7, Canada.

What is the SEC file number for Quantum Biopharma Ltd.?

The SEC file number for Quantum Biopharma Ltd. is 001-39152.

Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-10-22 07:54:45

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: October 22, 2024 By: /s/ Donal Carroll Donal Carroll, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description Exhibit 99.1 Press Release 3

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.